Sling Therapeutics Raises $123 Million to Advance an Oral Thyroid Eye Disease Drug

Sling Therapeutics has closed a $123 million Series C financing led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management, to advance the Phase 3 development of its oral small molecule IGF-1R inhibitor for thyroid eye disease.

The company has commenced its global Phase 3 ORBIT pivotal trial evaluating linsitinib, an oral inhibitor of the insulin-like growth factor 1 receptor, a validated biological target for thyroid eye disease, in adults with moderate to severe active disease. If approved, linsitinib would become the first oral drug available for thyroid eye disease, offering patients an alternative to the intravenous infusion treatments that currently dominate the category, including Amgen's Tepezza and Viridian Therapeutics' Lumvoa.

Competing on the axis that matters most to patients

Thyroid eye disease treatment today requires infusion therapy administered in a clinical setting, a meaningful burden for patients managing a chronic autoimmune condition that already affects their daily quality of life. An oral drug targeting the same validated mechanism as the existing infusion therapies does not need to prove a new biological thesis, IGF-1R inhibition is already clinically validated, it needs to prove it can deliver comparable efficacy through a dramatically more convenient route of administration. That is a narrower, more executable path to differentiation than pursuing a novel mechanism from scratch, and it is likely part of why Forbion and its co-investors were willing to commit $123 million to carry the program through a pivotal Phase 3 trial rather than an earlier-stage proof of concept. Being first to market with an oral option in a category currently defined entirely by infusion therapies also gives Sling a meaningful commercial window before any competitor with a similar oral mechanism could realistically reach approval.

What this means for founders

Sling Therapeutics' round illustrates a durable pattern in biotech fundraising: capital concentrates around programs that can convert a validated biological mechanism into a meaningfully better patient experience, rather than exclusively rewarding entirely novel science. For founders building in biotech or any regulated, capital-intensive category, the lesson generalizes: a large round at the pivotal-trial stage often reflects investor confidence in execution risk being the primary remaining variable, not scientific risk, which is a fundamentally different and typically more fundable position to raise from.

Biotech and healthcare investors can be found on the investor directory, and the free investor matching tool scores fit for clinical-stage biotech companies specifically. Background on how later-stage biotech rounds get structured is in the glossary entry on series-a progression. Currently live raises are visible on the live listings page, and broader biotech funding activity is tracked on the newsroom.

Find investors who are actively deploying by creating your pitch listing on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai